Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients

Samsung Medical Center

Status

Completed

Conditions

Schizophrenia

Schizoaffective Disorder

Study type

Observational

Funder types

Other

Industry

Identifiers

NCT01043250

2009-04-005

Details and patient eligibility

About

In this study, we are going to investigate quantitative and qualitative natures of appetite and eating-behavior changes induced by atypical antipsychotics, i.e., risperidone, olanzapine and aripiprazole, in schizophrenia patients.

Full description

This is an observational study. 2 Self-report questionnaires assessing changes of appetite and eating behaviors after medication are applied to patients who have been receiving one of the three atypical antipsychotics. We are going to compare changes of appetite and eating behaviors after medication between three atypical antipsychotics and investigate the association between changes of appetite and eating behaviors and changes of weight after medication.

Enrollment

81 patients

Sex

All

Ages

19 to 59 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients meeting the DSM-IV criteria of schizophrenia, schizophreniform disorder, or schizoaffective disorder
Male and female patients aged 19~59
Patients receiving monotherapy with one of the three AAPs, i.e., olanzapine, risperidone, and aripiprazole for more than two and less than 24 months
Patients who had at least one-week antipsychotics-free periods before starting the above antipsychotics
Clinically stable and able to complete the questionnaires
Patients who sufficiently understand the objective of the study and sign informed consent form

Exclusion criteria

Patients having any medical illness or taking any medicine affecting appetite and body weight
Patients with severe and unstable medical, neurological or systemic illnesses
Patients having any comorbid psychiatric disorders including substance use disorders and eating disorders.
Pregnant or breast-feeding women